Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 1.00 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.69 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.68 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.68 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.68 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | SHBG | P04278 | 2/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | G6PD | P11413 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5925374 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 | |
| SCHEMBL12825203 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 | |
| SCHEMBL1552239 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 | |
| SCHEMBL17817126 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 | |
| SCHEMBL1908291 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 | |
| SCHEMBL10273218 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 | |
| SCHEMBL12370187 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 | |
| SCHEMBL17341027 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 | |
| SCHEMBL20714758 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 | |
| SCHEMBL12178030 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B3AKR1B10AKR1B1OR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109956989-B | Recycling method of position isomer in preparation of 3 beta-acetoxyl-5 alpha-chlorine-6 beta-hydroxyandrost-17-one | 华东师范大学 | 2021-11-19 | — | — | CN | claimed |
| US-20160272670-A1 | STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM AND METHODS FOR THEIR PRODUCTION | UMECRINE AB (SE) | 2016-09-22 | — | — | US | claimed |
| US-20130102578-A1 | New Steroids Having Increased Water Solubility and Resistance Against Metabolism and Methods For Their Production | UMECRINE AB (SE) | 2013-04-25 | — | — | US | claimed |
| EP-2097437-A1 | THE USE OF PREGNANE AND ANDROSTANE STEROIDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISORDERS | Umecrine AB (SE) | 2009-09-09 | — | — | EP | claimed |
| WO-2009012955-A2 | PROCESS FOR THE PREPARATION OF DROSPIRENONE | NEWCHEM S.P.A. (IT) | 2009-01-29 | — | — | WO | claimed |
| WO-2008063128-A1 | THE USE OF PREGNANE AND ANDROSTANE STEROIDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2008-05-29 | — | — | WO | claimed |
| US-20080119416-A1 | NEW STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM, AND METHODS FOR THEIR PRODUCTION | UMECRINE AB (SE) | 2008-05-22 | — | — | US | claimed |
| EP-1351971-A2 | COMPOUNDS USEFUL FOR TREATING HYPERTRIGLYCERIDEMIA | Aeson Therapeutics Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002028880-A2 | COMPOUNDS USEFUL FOR TREATING HYPERTRIGLYCERIDEMIA | AESON THERAPEUTICS INC. (US) | 2002-04-11 | — | — | WO | claimed |
| EP-1163256-A1 | HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056757-A1 | IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | claimed |
| US-3968132-A | (17R)-Spiro-[androstane-17,1'-cyclobutan]-2'-ones, methods for their manufacture and intermediates useful therein | SCHERING CORPORATION (US) | 1976-07-06 | — | — | US | claimed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| CN-111971292-B | Glass formulations comprising steroid dimers and uses thereof | 波纹疗法公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240383941-A1 | 3-ALPHA SUBSTITUTED 3-BETA-HYDROXY-17-OXIMATED ANDROSTANE COMPOUND FOR MODULATION OF THE ALPHA-3 SUBTYPE OF THE GABAA RECEPTOR | UMECRINE AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-3985771-A | Total steroid synthesis employing substituted isoxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3984428-A | Isoxazolyl-substituted perhydrobenzindenes | HOFFMANN-LA ROCHE INC. (US) | 1976-10-05 | — | — | US | disclosed |
| US-3968132-A | (17R)-Spiro-[androstane-17,1'-cyclobutan]-2'-ones, methods for their manufacture and intermediates useful therein | SCHERING CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
| US-3968132-A | (17R)-Spiro-[androstane-17,1'-cyclobutan]-2'-ones, methods for their manufacture and intermediates useful therein | SCHERING CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383941-A1 | 3-ALPHA SUBSTITUTED 3-BETA-HYDROXY-17-OXIMATED ANDROSTANE COMPOUND FOR MODULATION OF THE ALPHA-3 SUBTYPE OF THE GABAA RECEPTOR | HSD3B1, HSD17B3, HSD3B2 | CYP19A1 20/4885HSD17B3 2/4885AKR1B10 319/4885 |
| US-20130102578-A1 | New Steroids Having Increased Water Solubility and Resistance Against Metabolism and Methods For Their Production | CYP11B1, CYP11A1, CYP11B2 | CYP19A1 35/4885HSD17B3 14/4885AKR1B10 170/4885 |
| US-20160272670-A1 | STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM AND METHODS FOR THEIR PRODUCTION | CYP11B1, CYP11A1, CYP11B2 | CYP19A1 35/4885HSD17B3 15/4885AKR1B10 197/4885 |
| US-20080119416-A1 | NEW STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM, AND METHODS FOR THEIR PRODUCTION | CYP21A2, CYP11B1, CYP11A1 | CYP19A1 32/4885HSD17B3 14/4885AKR1B10 161/4885 |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | CYP19A1 2989/4885HSD17B3 2385/4885AKR1B10 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.